ArticleJournal, genetic engineering & biotechnology2026
Relationship between expression of OGFR, P16, P21 and clinicopathological features of colorectal cancer patients.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the expression of OGFR, P16, and P21 in CRC patients and to perform a comprehensive analysis in relation to clinicopathological characteristics, overall survival (OS), and disease-free survival (DFS). The findings are expected to elucidate the roles of these molecules in CRC occurrence, progression, and prognosis, thereby providing potential theoretical evidence and practical directions for precision therapeutic strategies.
methodsBioinformatics analyses, including differential analysis, survival analysis, single-cell sequencing, and spatial transcriptome analysis, were conducted to assess OGFR. We employed RT-qPCR and Western blot techniques to quantify the mRNA and protein levels of OGFR, P16, and P21 in a cohort of 30 CRC tissues. Immunohistochemistry was applied to evaluate the positive expression rates of OGFR, P16, and P21 in 194 CRC tissues. Associations with clinicopathological features were analyzed using SPSS 20.0, and survival was assessed by the Kaplan-Meier method.
resultsOGFR was upregulated in CRC and associated with advanced stage and shorter DFS, while P16 and P21 were downregulated and correlated with tumor progression. Correlation analyses showed OGFR was negatively associated with P16 and P21, whereas P16 and P21 were positively correlated. Survival analysis indicated that P21 positivity predicted poorer OS, while both P16 and P21 positivity were linked to improved DFS.
conclusionsThis study highlights the regulatory relationships among OGFR, P16, and P21 in CRC, suggesting their potential as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.